<?xml version="1.0" encoding="UTF-8"?>
<p class="p">There are several diseases that activate the inflammatory process, and consequently a growing interest in substances with anti-inflammatory properties, in particular cyclodextrin inclusion complexes (CD-IC) which have used innovative biotechnology to increase the bioavailability, solubility and pharmacological effect of drugs [
 <xref rid="B27-ijms-20-00642" ref-type="bibr" class="xref">27</xref>,
 <xref rid="B28-ijms-20-00642" ref-type="bibr" class="xref">28</xref>,
 <xref rid="B29-ijms-20-00642" ref-type="bibr" class="xref">29</xref>]. The CD most commonly found in studies of CD-IC with anti-inflammatory activity is β-CD because of its good capacity for complexation with anti-inflammatory drugs, its appreciable oral acceptability, and low cost [
 <xref rid="B27-ijms-20-00642" ref-type="bibr" class="xref">27</xref>,
 <xref rid="B30-ijms-20-00642" ref-type="bibr" class="xref">30</xref>]. Recently, some interesting systematic reviews have strongly suggested that β-CD is a tool that can increase the bioavailability of these drugs and also produce better efficacy for analgesic and anti-inflammatory drugs [
 <xref rid="B24-ijms-20-00642" ref-type="bibr" class="xref">24</xref>,
 <xref rid="B27-ijms-20-00642" ref-type="bibr" class="xref">27</xref>]. 
</p>
